CX157 (proposed trade name TriRima, formerly Tyrima) is a
selective and
reversible inhibitor of MAO-A (RIMA). As of 2007 it was in
phase II clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s for the treatment of
depression.
[}] In 2013, work on the drug was terminate
References
Reversible inhibitors of MAO-A
Monoamine oxidase inhibitors
Abandoned drugs
Sulfur heterocycles
Trifluoromethyl compounds
Fluoroarenes
Sulfones
{{nervous-system-drug-stub